HRT and breast cancer risk, what to advise?

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 71, Issue 2, 1997, Pages 205-208

  Von Schoultz, Bo ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

breast cancer; HRT; progestogen

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; CANCER RISK; CONFERENCE PAPER; DRUG EFFECT; DRUG INDICATION; FEMALE; HORMONE SUBSTITUTION; HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 0031081142     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(96)02636-X     Document Type: Conference Paper

References (27)

1. Alanko A, Heinonen E, Sceinin T, Tolpanen EM, Vihko R. Significance of estrogen and progesterone receptors, disease free interval, and site of first metastasis on survival of breast cancer patients. Cancer 1985; 56: 1696-1700.
2. Anderson TJ, Battersby S, King RBJB, McPherson K, Going JJ. Oral contraceptive use influences breast cell proliferation. Hum Pathol 1989; 20: 1139-1141.
3. Bergkvist L, Adami H-O, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989; 321: 293-297.
4. Brinton LA, Hoover R, Fraumeni Jr JF. Menopausal oestrogens and breast cancer risk: an expanded case control study. Br J Cancer 1986; 54: 825-832.
5. Cancer Incidence in Sweden, 1992. Health and Disease. National Board of Health and Welfare, Centre of Epidemiology, 1995;1.
6. Cline JM, Söderqvist G, von Schoultz E, Skoog L, von Schoultz B. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am J Obstet Gynecol 1996; 174: 93-100.
7. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol 1993; 168: 1473-1480.
8. Colditz GA, Hankinson SE, Hunter DJ, Wilett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589-1593.
9. Donegan WL, Spratt JS. Cancer of the Breast, 4th edn. Philadelphia: WB Saunders 1995.
10. Ewertz M. Influence of non-contraceptive exogenous and endogenous hormones on breast cancer risk in Denmark. Int J Cancer 1988; 442: 832-838.
11. Gompel A, Malet C, Spritzer P, Lalardrie JP, Kuttenn F, Mauvais-Jarvis P. Progestine effect on cell proliferation and 17 β-hydroxysteroi dehydrogenase activity in normal human breast cells in culture. J Clin Endocrinol Metab 1986; 63: 1174-1180.
12. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Int Med 1992; 117: 1016-1037.
13. Kaufman DW, Palmer JR, de Mouzon J, et al. Estrogen replacment therapy and the risk of breast cancer. Results from a case-control surveillance study. Am J Epidemiol 1991; 134: 1375-1385.
14. Kvåle G. Reproductive factors in breast cancer epidemiology. Acta Oncol 1992; 31: 187-194.
15. La Veccia C, Decarli A, Pazzarini F, Gentile A, Liberati C, Franceschi S. Noncontraceptive estrogens and the risk of breast cancer in women. Int J Cancer 1986; 38: 853-858.
16. Longacre TA, Bartow SA. A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Pathol 1986; 10: 382-393.
17. Mauvais-Jarvis P, Kuttenn F, Gompel A. Antiestrogen action of progesterone in breast tissue. Breast Cancer Res Treatment 1986; 8: 179-188.
18. Pike MC. Hormonal contraception with LHRHJ agonists and the prevention of breast and ovarian cancer. In: Mann RD, ed. Oral Contraceptives and Breast Cancer. Lancaster: Parthenon, 1990, pp. 323-348.
19. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation and breast cancer risk. Epidemiol Rev 1993; 15: 17-35.
20. Ravnikar VA. Compliance with hormone replacement therapy: are women receiving the full impact of hormone repla cement therapy preventive health benefits? Womens Health Issues 1992; 2: 75-80.
21. Risch HA, Howe GR. Menopausal hormone usage and breast cancer in Saskatchewan: A record-linkage cohort study. Am J Epidemiol 1994; 139: 670-683.
22. Schairer C, Byrne C, Keyl PM, Brinton LA, Sturgeon SR, Hoover RN. Menopausal estrogen and estrogen-progestin replacement therapy and the risk of breast cancer. Cancer Causes Control 1994; 5: 491-500.
23. Söderqvist G, von Schoultz B, Tani E, Skoog L. Proliferation of breast epithelial cells in healthy women during the menstrual cycle. Am J Obstet Gynecol, 1996 (in press).
24. Söderqvist G. Sex steroid effects on normal breast tissue. Thesis, Karolinska Institute, 1996.
25. Thomas DP, Pershing JP, Hutchinson WB. Exogenous estrogens and other risk factors for breast cancer in women with benign breast disease. JNCI 1982; 69: 017-1023.
26. Wingo PA, Layde PM, Lee NC, et al. The risk of breast cance in menopausal women who have used estrogen replacement therapy. JAMA 1987; 257: 209-215.
27. Yang CP, Daling JR, Band PR, Gallagher RP, White E, Weiss NS. Noncontraceptive hormone use and risk of breast cancer. Cancer Causes Control 1992; 3: 475-479.